Oriola Oyj (HEL:ORIOLA)
Finland
· Delayed Price · Currency is EUR | Market Cap | 173.95M |
| Revenue (ttm) | 1.91B |
| Net Income (ttm) | -27.20M |
| Shares Out | 185.25M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | 10.06 |
| Dividend | 0.07 (7.45%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 91,977 |
| Average Volume | 147,429 |
| Open | 0.940 |
| Previous Close | 0.939 |
| Day's Range | 0.932 - 0.952 |
| 52-Week Range | 0.920 - 1.260 |
| Beta | 0.49 |
| RSI | 37.86 |
| Earnings Date | Apr 29, 2026 |
About Oriola Oyj
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, ... [Read more]
Financial Performance
In 2025, Oriola Oyj's revenue was 1.91 billion, an increase of 13.40% compared to the previous year's 1.68 billion. Losses were -27.20 million, 35.3% more than in 2024.
Financial StatementsNews
Oriola Oyj Annual Shareholders Meeting Transcript
Oriola Oyj Annual Shareholders Meeting Transcript
Q4 2025 Oriola Oyj Earnings Call Transcript
Q4 2025 Oriola Oyj Earnings Call Transcript
Oriola Oyj Earnings Call Transcript: Q4 2025
Net sales rose 14% and Adjusted EBITDA reached EUR 35.1 million, driven by strong growth in both distribution and wholesale segments, despite a negative net profit due to ERP and JV-related costs. Cash flow and liquidity improved, and a new automated distribution center was announced.
Q3 2025 Oriola Oyj Earnings Call Transcript
Q3 2025 Oriola Oyj Earnings Call Transcript
Oriola Oyj Earnings Call Transcript: Q3 2025
Net sales rose 9% year-over-year to EUR 463 million, with Adjusted EBITDA improving to EUR 9.6 million, driven by both distribution and wholesale segments. The ERP project and impairments weighed on reported EBITDA and net profit, but outlook for EBITDA growth remains unchanged.
Oriola Oyj Earnings Call Transcript: Q2 2025
Q2 saw 12% net sales growth, led by strong Distribution and Wholesale segments, though Wholesale profitability declined. Cost controls and efficiency measures are in place, with H2 expected to improve and adjusted EBITDA to grow above 3% for the year.
Oriola Oyj Earnings Call Transcript: Q1 2025
Q1 2025 saw 19% net sales growth (8% organic), margin improvement, and strong cash flow, despite higher costs from strategic investments and ERP expenses. Distribution outperformed, while wholesale faced margin pressure. Outlook remains positive, with EBITDA expected to rise.
Oriola Oyj Earnings Call Transcript: Q4 2024
Full-year organic net sales grew 3% to EUR 1.7 billion, with adjusted EBIT up 30% year-over-year. Distribution and wholesale segments drove profitability, while Kronans Apotek JV underperformed but saw strong e-commerce growth. Adjusted EBITDA is expected to increase in 2025.
Oriola Oyj Earnings Call Transcript: Q3 2024
Q3 saw 19% net sales growth and a 25% rise in adjusted EBIT, driven by distribution segment gains and cost efficiencies. Guidance for higher full-year adjusted EBIT is maintained, with ongoing ERP investments and a strong cash position supporting future growth.
Oriola Oyj Earnings Call Transcript: Q2 2024
Net sales rose 13% year-over-year to EUR 440 million, with adjusted EBIT up 53% to EUR 5.1 million, driven by growth in both distribution and wholesale segments. Debt was significantly reduced, and the financial position remains strong, while guidance for 2024 is unchanged.